News
A Major Advance in Pancreatic Cancer Care
A promising new drug called daraxonrasib nearly doubled survival rates for... Here goes the content ...
Combining blood biomarkers with cognitive testing improves prediction of functional decline in people at risk for Alzheimer’s disease. Researchers at the Diabetes Research Institute are using engineering-based models to investigate how lymph node environments may drive type 1 diabetes. The $10 million donation will enable Dr. Field F. Willingham to advance the growth of a division focused on innovation. Tumor-on-a-chip model reveals how pancreatic cancer co-opts immune cells to drive growth, opening new paths for therapy.
Blood Biomarkers and Cognitive Testing Improve Prediction of Early Alzheimer’s Decline
Engineering New Clues to Type 1 Diabetes at the Diabetes Research Institute
Gift from Citadel Founder and CEO Kenneth C. Griffin Brings Eminent Gastroenterologist to Miller School and UHealth as Division Chief
Tumor-on-a-Chip Reveals How Pancreatic Cancer Hijacks the Immune System
